JP5240476B2 - ２−［４−（３−及び２−フルオロベンジルオキシ）ベンジルアミノ］プロパンアミドの製造方法 - Google Patents

２−［４−（３−及び２−フルオロベンジルオキシ）ベンジルアミノ］プロパンアミドの製造方法 Download PDF

Info

Publication number
JP5240476B2
JP5240476B2 JP2009515731A JP2009515731A JP5240476B2 JP 5240476 B2 JP5240476 B2 JP 5240476B2 JP 2009515731 A JP2009515731 A JP 2009515731A JP 2009515731 A JP2009515731 A JP 2009515731A JP 5240476 B2 JP5240476 B2 JP 5240476B2
Authority
JP
Japan
Prior art keywords
fluorobenzyloxy
benzaldehyde
fluorobenzyl
propanamide
benzylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009515731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009541232A5 (enExample
JP2009541232A (ja
Inventor
バルバンテイ，エレナ
カツチア，カルラ
サルバツテイ，パトリシア
ベラルデイ，フランチエスコ
ルフイリ，テイツイアーノ
ボゴーニヤ，ルイジイ
Original Assignee
ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37101658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5240476(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー filed Critical ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー
Publication of JP2009541232A publication Critical patent/JP2009541232A/ja
Publication of JP2009541232A5 publication Critical patent/JP2009541232A5/ja
Application granted granted Critical
Publication of JP5240476B2 publication Critical patent/JP5240476B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/08—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C07C233/13—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/16—Preparation of optical isomers
    • C07C231/18—Preparation of optical isomers by stereospecific synthesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009515731A 2006-06-19 2007-06-08 ２−［４−（３−及び２−フルオロベンジルオキシ）ベンジルアミノ］プロパンアミドの製造方法 Active JP5240476B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06012565 2006-06-19
EP06012565.5 2006-06-19
PCT/EP2007/005105 WO2007147491A1 (en) 2006-06-19 2007-06-08 Process for the production of 2- [4 - ( 3- and 2-flu0r0benzyl0xy) benzylamin0] propan amides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013002429A Division JP5795342B2 (ja) 2006-06-19 2013-01-10 ２−［４−（３−及び２−フルオロベンジルオキシ）ベンジルアミノ］プロパンアミドの製造方法

Publications (3)

Publication Number Publication Date
JP2009541232A JP2009541232A (ja) 2009-11-26
JP2009541232A5 JP2009541232A5 (enExample) 2010-08-12
JP5240476B2 true JP5240476B2 (ja) 2013-07-17

Family

ID=37101658

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009515731A Active JP5240476B2 (ja) 2006-06-19 2007-06-08 ２−［４−（３−及び２−フルオロベンジルオキシ）ベンジルアミノ］プロパンアミドの製造方法
JP2013002429A Active JP5795342B2 (ja) 2006-06-19 2013-01-10 ２−［４−（３−及び２−フルオロベンジルオキシ）ベンジルアミノ］プロパンアミドの製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013002429A Active JP5795342B2 (ja) 2006-06-19 2013-01-10 ２−［４−（３−及び２−フルオロベンジルオキシ）ベンジルアミノ］プロパンアミドの製造方法

Country Status (26)

Country Link
US (2) US8076515B2 (enExample)
EP (2) EP2029524B1 (enExample)
JP (2) JP5240476B2 (enExample)
KR (2) KR101491541B1 (enExample)
CN (2) CN101472880B (enExample)
AR (1) AR061510A1 (enExample)
AU (1) AU2007263328C1 (enExample)
BR (1) BRPI0712936B8 (enExample)
CA (1) CA2653012C (enExample)
CY (2) CY1115951T1 (enExample)
DK (2) DK2029524T3 (enExample)
EA (2) EA025326B1 (enExample)
ES (2) ES2602069T3 (enExample)
HR (2) HRP20150136T1 (enExample)
HU (1) HUE030233T2 (enExample)
IL (1) IL195294A (enExample)
LT (1) LT2474521T (enExample)
MX (2) MX2008015704A (enExample)
NO (2) NO342018B1 (enExample)
NZ (2) NZ572798A (enExample)
PL (2) PL2029524T3 (enExample)
PT (2) PT2029524E (enExample)
RS (2) RS55464B1 (enExample)
SI (2) SI2029524T1 (enExample)
TW (2) TWI393700B (enExample)
WO (1) WO2007147491A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070276046A1 (en) * 2003-08-25 2007-11-29 Patricia Salvati Alpha-Aminoamide Derivatives Useful as Anti-Inflammatory Agents
KR101491541B1 (ko) * 2006-06-19 2015-02-09 뉴론 파마슈티칼즈 에스. 피. 에이. 2-［4-(3- 및 2-플루오로벤질옥시)벤질아미노)프로판 아미드의 제조방법
EP3257842B1 (en) * 2007-12-11 2020-11-18 Newron Pharmaceuticals S.p.A. Therapeutic use of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree
EP2314569A1 (en) 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
LT2563355T (lt) * 2010-04-27 2016-09-26 Newron Pharmaceuticals S.P.A. Ralfinamido metansulfonato druskų arba jų r-enentiomerų gavimo būdas
KR20150090100A (ko) 2012-12-03 2015-08-05 에프. 호프만-라 로슈 아게 스테아로일-CoA 불포화화효소 1(에스씨디 1)의 억제제로서의 치환된 이속사졸 아마이드 화합물
US9475757B2 (en) 2013-05-03 2016-10-25 Council Of Scientific & Industrial Research Synthesis of anti-Parkinson agent
CN104292128A (zh) * 2014-07-01 2015-01-21 南京正科制药有限公司 一种沙芬酰胺晶型a
JP6466109B2 (ja) * 2014-09-09 2019-02-06 東ソー・ファインケム株式会社 ２−ベンジルオキシ−５−（トリフルオロメチル）ピリミジン誘導体及びその製造方法
CN105017060B (zh) * 2015-07-03 2017-06-16 南京正大天晴制药有限公司 一种沙芬酰胺新晶型及其制备方法
CN106365966A (zh) * 2015-07-24 2017-02-01 上海医药集团股份有限公司 一种苄基芳基醚的制备方法
CN105061245A (zh) * 2015-08-25 2015-11-18 成都维恒医药科技有限公司 一种高纯度沙芬酰胺的制备方法
CN106220525A (zh) * 2016-07-31 2016-12-14 合肥远志医药科技开发有限公司 一种工业化沙芬酰胺甲磺酸盐的制备方法
CN106336363B (zh) * 2016-08-22 2018-10-30 上海医药集团股份有限公司 一种沙芬酰胺甲磺酸盐晶型c及其制备方法
CN106565521B (zh) * 2016-08-24 2019-03-08 浙江美诺华药物化学有限公司 (s)-2-[3-(3-氟苄基)-4-(3-氟苄氧基)苄氨基]丙酰胺及其盐的制备方法
CN106596828B (zh) * 2016-12-15 2018-09-25 扬子江药业集团有限公司 一种甲磺酸沙芬酰胺有关物质的检测方法
CN107271600B (zh) * 2017-07-28 2019-01-25 成都百裕制药股份有限公司 一种4-(3-氟苄氧基)苯甲醛中异构体杂质含量的检测方法
CN107857713A (zh) * 2017-11-23 2018-03-30 江苏恒盛药业有限公司 一种沙芬酰胺氢溴酸盐及其一种晶型
CN107759487A (zh) * 2017-11-23 2018-03-06 江苏恒盛药业有限公司 一种沙芬酰胺盐酸盐及其一种晶型以及制备方法
WO2019167085A1 (en) * 2018-03-01 2019-09-06 Msn Laboratories Private Limited, R&D Center Process for the preparation of (s)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino propanamide methanesulfonate
US11111208B2 (en) 2019-06-17 2021-09-07 RK Pharma Solutions LLC Process for the preparation of safinamide mesylate intermediate
US11225457B2 (en) 2019-08-06 2022-01-18 Medichem, S.A. Process for preparing safinamide
CN111122736B (zh) * 2019-12-30 2021-03-12 北京鑫开元医药科技有限公司海南分公司 一种用于检测布瓦西坦中间体中对映异构体的方法
CN113214097B (zh) * 2020-01-21 2022-08-30 厦门大学 治疗阿尔茨海默病的化合物
CN112028754A (zh) * 2020-06-17 2020-12-04 浙江美诺华药物化学有限公司 一种甲磺酸沙芬酰胺中间体的制备方法
CN114088830B (zh) * 2021-11-10 2022-09-23 石家庄四药有限公司 一种4-(3-氟苄氧基)苯甲醛中异构体的检测方法
CN117923998A (zh) * 2022-10-24 2024-04-26 中国石油化工股份有限公司 苯甲醛及其衍生物的制备方法
CN116008439B (zh) * 2023-02-20 2023-10-27 山东绿叶制药有限公司 一种检测2,6-二氧杂螺[4,5]癸烷类化合物或其盐中杂质的方法
EP4750446A1 (en) 2023-07-25 2026-06-03 Intas Pharmaceuticals Ltd. An orodispersible pharmaceutical solid dosage form of safinamide

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
JP2003529589A (ja) 2000-03-31 2003-10-07 ユーロ−セルティック エス． ア． アミノピリジンならびにこれらの鎮痙薬およびナトリウムチャンネル遮断薬としての使用
CN1274306C (zh) 2001-09-03 2006-09-13 纽朗制药有限公司 包含加巴喷丁或其类似物和α－氨基酰胺的药物组合物及其止痛应用
EP1438956A1 (en) 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
AU2004207010A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
CA2514574A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
US20070276046A1 (en) 2003-08-25 2007-11-29 Patricia Salvati Alpha-Aminoamide Derivatives Useful as Anti-Inflammatory Agents
EP1524267A1 (en) 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Substituted benzylaminoalkylene heterocycles
EP1557166A1 (en) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
RS51411B (sr) 2004-09-10 2011-02-28 Newron Pharmaceuticals S.P.A. Upotreba (r)-(halobenziloksi) benzilamino-propanamida kao selektivnih modulatora natrijumovih i/ili kalcijumovih kanala
EP1870097A1 (en) 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
KR101491541B1 (ko) * 2006-06-19 2015-02-09 뉴론 파마슈티칼즈 에스. 피. 에이. 2-［4-(3- 및 2-플루오로벤질옥시)벤질아미노)프로판 아미드의 제조방법
EP3257842B1 (en) 2007-12-11 2020-11-18 Newron Pharmaceuticals S.p.A. Therapeutic use of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree
CN101903021B (zh) 2007-12-19 2012-11-14 纽朗制药有限公司 用于治疗精神病的α-氨基酰胺衍生物

Also Published As

Publication number Publication date
RS53824B1 (sr) 2015-06-30
AU2007263328A2 (en) 2009-02-19
CN101472880B (zh) 2013-04-24
HK1130245A1 (en) 2009-12-24
US20120157712A1 (en) 2012-06-21
AU2007263328C1 (en) 2012-09-06
CY1115951T1 (el) 2017-01-25
SI2029524T1 (sl) 2015-03-31
KR101491541B1 (ko) 2015-02-09
IL195294A (en) 2015-03-31
MX2008015704A (es) 2009-01-09
US20090156678A1 (en) 2009-06-18
NO20090231L (no) 2009-01-16
KR101410291B1 (ko) 2014-06-20
CA2653012C (en) 2014-08-05
ES2602069T3 (es) 2017-02-17
KR20140027563A (ko) 2014-03-06
BRPI0712936A2 (pt) 2012-12-18
AU2007263328A1 (en) 2007-12-27
TWI412512B (zh) 2013-10-21
DK2474521T3 (en) 2016-10-31
EP2474521B1 (en) 2016-08-10
US8076515B2 (en) 2011-12-13
JP2013139446A (ja) 2013-07-18
NZ572798A (en) 2011-11-25
KR20090021392A (ko) 2009-03-03
IL195294A0 (en) 2009-08-03
EP2474521A1 (en) 2012-07-11
US8278485B2 (en) 2012-10-02
JP5795342B2 (ja) 2015-10-14
SI2474521T1 (sl) 2016-12-30
DK2029524T3 (da) 2015-02-23
MX342698B (es) 2016-10-10
EA200970028A1 (ru) 2009-06-30
EP2029524B1 (en) 2014-11-26
PL2474521T3 (pl) 2017-01-31
CN103284984A (zh) 2013-09-11
BRPI0712936B1 (pt) 2021-02-23
NZ595737A (en) 2013-04-26
EP2029524A1 (en) 2009-03-04
TW201313662A (zh) 2013-04-01
TWI393700B (zh) 2013-04-21
PL2029524T3 (pl) 2015-04-30
WO2007147491A1 (en) 2007-12-27
HRP20150136T1 (xx) 2015-03-13
CA2653012A1 (en) 2007-12-27
EA017123B1 (ru) 2012-10-30
RS55464B1 (sr) 2017-04-28
CY1118113T1 (el) 2017-06-28
HRP20161456T1 (hr) 2016-12-16
NO20171916A1 (no) 2009-01-16
NO342644B1 (no) 2018-06-25
EA025326B1 (ru) 2016-12-30
NO342018B1 (no) 2018-03-12
HUE030233T2 (en) 2017-04-28
PT2029524E (pt) 2015-03-09
LT2474521T (lt) 2016-11-25
JP2009541232A (ja) 2009-11-26
AR061510A1 (es) 2008-09-03
BRPI0712936B8 (pt) 2021-05-25
CN101472880A (zh) 2009-07-01
AU2007263328B2 (en) 2012-03-22
ES2527437T3 (es) 2015-01-26
CN103284984B (zh) 2016-08-03
PT2474521T (pt) 2016-11-10
EA201101308A1 (ru) 2012-02-28
TW200815322A (en) 2008-04-01

Similar Documents

Publication Publication Date Title
JP5795342B2 (ja) ２−［４−（３−及び２−フルオロベンジルオキシ）ベンジルアミノ］プロパンアミドの製造方法
JP2009541232A5 (enExample)
JP5460613B2 (ja) 高純度を有する２−［４−（３−または２−フルオロベンジルオキシ）ベンジルアミノ］プロパンアミドの製造方法
HK1188942B (en) Process for the production of 2-[4-(3-and 2-flu0r0benzyl0xy) benzylamin0]propanamides
HK1130245B (en) Process for the production of 2-[4-(3-and 2-fluorobenzyloxy) benzylamino] propanamides
HK1188942A (en) Process for the production of 2-[4-(3-and 2-flu0r0benzyl0xy) benzylamin0]propanamides
HK1145673B (en) Process for the production of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100604

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100604

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130305

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20130305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130319

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160412

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5240476

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250